NEO — Stock Film
STOCK FILMSCENE 1/11NEO · $14.24
Stock Expert AI presents
NEO
NeoGenomics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
NeoGenomics, Inc. A quick introduction.

On the stock market since 2004, it operates in the world of health and science. It has 2,500 employees. Now — the numbers.

on the stock market since 2004
2,500 employees
$370.8M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales are growing, year after year.

Average growth of 11% a year over the last 4 years. Red columns mark years that ended in a loss.

$484.3M
2021
$509.7M
2022
$591.6M
2023
$660.6M
2024
$727.3M
2025
In the vault right now:
$0
DEBT: $472.3M
At this pace, that money lasts about 1.5 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
61
average

Profit indicators sit around the sector average.

FINANCIAL STRENGTH
44
weak

Clearly below the class average.

VALUATION
77
strong

Clearly above the class average — a step short of the very top.

GROWTH
56
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
92
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
WEAK SPOTS
Heavy bets against the stock4/10
WORTH WATCHING

Bets Against the Stock: The number of investors betting on a fall stands out.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 73% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 13% a year on average.

2
THE BRIGHT SIDE · 2/3
Sales are holding up

The company sells $727.3M a year; the problem isn’t sales — it’s costs running above that number.

3
THE BRIGHT SIDE · 3/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

1
THE RISKS · 1/2
The losses continue

A loss of $108.0M against $727.3M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, NEO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: NEO has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film